Zobrazeno 1 - 10
of 33
pro vyhledávání: '"C E, Walsh"'
Autor:
H. Chao, C. E. Walsh
Publikováno v:
Haemophilia. 8:60-67
Gene therapy may revolutionize the treatment of haemophilia. Effective gene therapy requires sustained therapeutic levels of factors IX (FIX) and VIII. Adeno-associated virus (AAV) is a member of the parvovirus family, is a nonpathogenic virus with a
Publikováno v:
Haemophilia : the official journal of the World Federation of Hemophilia. 18(4)
Acute haemorrhage treatment in patients with congenital haemophilia with inhibitors (CHwI) has transitioned to home. Patient/caregiver perceptions of bleeding symptoms and reasons for starting/stopping treatment were investigated. Frequently bleeding
Publikováno v:
Haemophilia : the official journal of the World Federation of Hemophilia. 18(3)
Patients with congenital haemophilia with inhibitors experience acute bleeds managed with bypassing agents, such as recombinant FVIIa (rFVIIa). Home-based treatment and dosing patterns in the US remain poorly described. This study aimed to assess the
Autor:
C. E. Walsh
Publikováno v:
New Zealand Economic Papers. 25:141-150
The Reserve Bank Act of 1989 can be viewed as a means of providing credibility to the Reserve Bank's attempts to lower inflation and as a solution to the inflationary bias inherent in the discretionary conduct of monetary policy. Many of the critics
Autor:
C. E. Walsh
Publikováno v:
Haemophilia : the official journal of the World Federation of Hemophilia. 14(2)
Publikováno v:
Archives of Disease in Childhood - Fetal and Neonatal Edition. 96:Fa89-Fa90
Aim The persistent rise in the rate of caesarean section (CS) is a prominent and contentious feature of modern obstetrics. The aim of this study was to determine which clinical subgroups contributed to an unexpected decline in the CS rate at our inst
Publikováno v:
Blood. 95(5)
Persistent therapeutic levels of human factor VIII (hFVIII) would signify a major advance in the treatment of hemophilia A. Here we report sustained expression of hFVIII in immunocompetent mice using recombinant adeno-associated virus (rAAV) vectors.
Publikováno v:
Blood. 95(2)
Fanconi anemia (FA) is a genetic disorder characterized by bone marrow failure, congenital anomalies, and a predisposition to malignancy. FA cells demonstrate hypersensitivity to DNA cross-linking agents, such as mitomycin C (MMC). Mice with a target
Publikováno v:
Human genetics. 102(2)
Fanconi anemia (FA) is an autosomal recessive disorder characterized by bone marrow failure, cancer susceptibility, and a variety of developmental defects. The disease is clinically heterogeneous; eight different complementation groups (FA A-H) and,
Publikováno v:
Blood. 90(9)
Fanconi anemia (FA) is an autosomal recessive genetic disorder characterized by a variety of physical anomalies, bone marrow failure, and an increased risk for malignancy. FA cells exhibit chromosomal instability and are hypersensitive to DNA cross-l